Results 81 to 90 of about 33,884 (207)

On Hierarchical Composite Endpoints in Pediatric Cancer Supportive Care: Illustrative Examples From Two Multi‐Center Phase‐III Randomized Clinical Trials

open access: yesPediatric Blood &Cancer, Volume 73, Issue 9, September 2026.
ABSTRACT Pediatric supportive care clinical trials often involve multiple clinically important outcomes, complicating trial interpretation. Hierarchical composite endpoints (HCEs) provide a framework to integrate key outcomes according to clinical importance.
Willem H. Collier   +11 more
wiley   +1 more source

Differences in the Prognostic Value of Tumor Extent of Resection among the Molecular Subgroups of Medulloblastoma: A Single Centre Study of 113 Cases

open access: yesBrain Science Advances, 2017
Medulloblastoma (MB) is one of the most common pediatrics malignant tumors of the central nervous system. Studies in America and Europe have demonstrated significant differences in the prognostic value of medulloblastoma extent among molecular subgroups ...
Yuyuan Wang   +8 more
doaj   +1 more source

UGT1A1 genotype testing for irinotecan: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

open access: yesBritish Journal of Clinical Pharmacology, Volume 92, Issue 9, Page 2986-3001, September 2026.
Abstract Irinotecan, a topoisomerase I inhibitor, is available as both non‐pegylated and pegylated formulations. The non‐pegylated formulation is licensed for use in advanced colorectal cancer either in combination with other agents or as monotherapy.
Dharmisha Chauhan   +24 more
wiley   +1 more source

Natural Compounds Targeting Oncogenic Signaling Networks in Glioblastoma: Molecular Mechanisms, Translational Advances, and Clinical Perspectives

open access: yesBrain and Behavior, Volume 16, Issue 9, September 2026.
Glioblastoma (GBM) is a highly aggressive brain tumor with a poor prognosis, driven by abnormal signaling pathways that promote growth and resistance to treatment. Conventional therapies are inadequate, highlighting the need for novel multitargeted approaches.
Mehrukh Zehravi   +13 more
wiley   +1 more source

Cyclins and Cyclin‐Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer

open access: yesMedComm, Volume 7, Issue 9, September 2026.
This work synthesizes recent insights into the pathological roles of cyclins and cyclin‐dependent kinases (CDKs) across human cancers, highlights state‐of‐the‐art innovative approaches (especially targeted degradation and redistribution of CDK/cyclin proteins) for cancer therapy, and outlines future directions for CDK/cyclin‐related biomedical research.
Suya Zheng   +9 more
wiley   +1 more source

RNA‐Binding Proteins: Function, Biological Mechanisms, and Therapeutic Opportunities

open access: yesMedComm, Volume 7, Issue 9, September 2026.
RNA‐binding proteins (RBPs) regulate RNA stability, localization, translation, and splicing through intrinsic binding domains and interactions with diverse cellular partners. Their competitive and cooperative networks shape disease‐related RNA programs, especially in cancer.
Ling Li, Xiuli Yan, Qing Ji, Hui Zhang
wiley   +1 more source

Inhibition of STAT3: A promising approach to enhancing the efficacy of chemotherapy in medulloblastoma

open access: yesTranslational Oncology
Medulloblastoma is a type of brain cancer that primarily affects children. While chemotherapy has been shown to be effective in treating medulloblastoma, the development of chemotherapy resistance remains a challenge.
Sachindra Kumar   +7 more
doaj   +1 more source

Clinical and molecular features of primary gliosarcoma with digital spatial whole‐transcriptome analysis of glial and mesenchymal components

open access: yesBrain Pathology, Volume 36, Issue 5, September 2026.
We report the clinical and genetic features of an institutional cohort of primary adult gliosarcomas compared to glioblastoma. We performed spatial whole‐transcriptome analysis on glial and sarcomatous regions of four cases to compare gene expression profiles and validated differential protein expression for two markers in tissue sections.
Matthew D. Wood   +6 more
wiley   +1 more source

Molecular and clinical features of a Japanese medulloblastoma cohort: Subgroup‐specific prognostic stratification using economical/accessible diagnostic methods

open access: yesBrain Pathology, Volume 36, Issue 5, September 2026.
This study characterizes the molecular subgroup–specific features of a nationwide Japanese cohort comprising 242 medulloblastomas (MBs). Furthermore, we introduce SEE‐6‐CNA, a simple, cost‐effective, and FFPE‐compatible molecular test that is applicable to routine pathology samples and serves as a surrogate for risk stratification in non‐WNT/non‐SHH ...
Kohichi Go   +70 more
wiley   +1 more source

Mapping naturally presented T cell antigens in medulloblastoma based on integrative multi-omics

open access: yesNature Communications
Medulloblastoma is the most frequent malignant primary brain tumor in children. Despite recent advances in integrated genomics, the prognosis in children with high-risk medulloblastoma remains devastating, and new tumor-specific therapeutic approaches ...
Julia Velz   +36 more
doaj   +1 more source

Home - About - Disclaimer - Privacy